Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Core Insights - Bicara Therapeutics has selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial, with an interim analysis expected by mid-2027 [1][5] - The company announced a new dosing regimen for ficerafusp alfa, which includes a less frequent loading and every-three-week maintenance dose [1][5] - Bicara's CEO highlighted the company's strong momentum in clinical, regulatory, and corporate priorities, emphasizing the potential impact on patients with HPV-negative head and neck cancer [2] Clinical Development - The FORTIFI-HN01 trial is a pivotal Phase 2/3 study focusing on ficerafusp alfa for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma [3] - Ongoing Phase 1b expansion cohorts are evaluating ficerafusp alfa both as a monotherapy and in combination with pembrolizumab for patients with third-line or greater metastatic colorectal cancer [3][7] - Data presented at various conferences indicated that ficerafusp alfa is well-tolerated and shows promising efficacy, supporting the higher dose selection [5] Financial Highlights - Bicara raised net proceeds of $161.8 million through an oversubscribed public offering, aimed at enhancing its medical and commercial infrastructure [4][6] - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $414.8 million, down from $489.7 million in 2024 [12] - Research and development expenses for Q4 2025 were $33.0 million, compared to $19.9 million in Q4 2024, reflecting increased costs associated with clinical trials [12] Upcoming Milestones - The company anticipates substantial enrollment in the FORTIFI-HN01 pivotal study by the end of 2026, enabling an interim analysis readout in mid-2027 [11] - Bicara plans to present long-term follow-up data from the Phase 1b study at the 2026 ASCO Annual Meeting [11] - The company aims to make critical commercial hires, including a Chief Commercial Officer, by the end of 2026 to prepare for potential product launch [11]